BrightGene Bio-medical Technology(SH:688166) GLP1减重宝典·2025-09-17 04:03Core Viewpoint - The article discusses the clinical trial approval for BGM0504, a dual agonist of GLP-1 and GIP receptors, which is expected to have potential in treating various metabolic diseases, including obesity and non-alcoholic steatohepatitis (NASH) [4][6]. Group 1: Clinical Trial and Drug Development - On September 16, Borui Biopharmaceuticals (Suzhou) Co., Ltd. announced that its subsidiary Borui Pharmaceutical (Suzhou) Co., Ltd. received the clinical trial approval notice from the National Medical Products Administration to conduct trials of BGM0504 tablets in overweight and obese adults [4]. - BGM0504 is designed to activate two downstream signaling pathways, which can help control blood sugar levels, reduce weight, and improve conditions like NASH [6]. - Currently, the injectable form of BGM0504 is in Phase III clinical trials for two indications: type 2 diabetes and weight loss, while the tablet form is being developed for oral administration [7]. Group 2: GLP-1 Drug Class Overview - GLP-1 (glucagon-like peptide-1) is a hormone produced by intestinal L cells and is classified as an incretin. GLP-1 receptor agonists are a new class of hypoglycemic drugs that enhance insulin secretion in a glucose-dependent manner, suppress glucagon secretion, and delay gastric emptying, leading to reduced food intake and lower blood sugar levels [17].